You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Principled Design of an Augmented Reality Trainer for Medics

    SBC: UNVEIL LLC            Topic: DHP17A003

    Augmented reality (AR) offers the ability to enhance existing combat medic training by including perceptual cues and adaptive training elements to traditional simulation-based training using manikins. Unveil has developed a training system called the Macrocognitive AR Trainer (MART). MART is designed to foster the development of macrocognitive skills (e.g., sensemaking, assessment skills, mental m ...

    STTR Phase II 2018 Department of DefenseDefense Health Agency
  3. Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients

    SBC: Mercury Biomed LLC            Topic: 300

    Project SummaryAbstractThis proposal presents Phase II of Mercury Biomedandapos s plan for commercializing the new and innovative WarmSmart technology to more effectively keep surgical patients normothermicWarmSmart embodies several breakthrough concepts in bioheat transfer to manage core temperatureWe are building a costcompetitive patient warming technology that will be superior to existing tech ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Dynamic virtual moulage based on thin film adhesive displays

    SBC: ARCHIE MD INC.            Topic: DHA17A002

    Providing Army combat medics with meaningful experience in treatment of battlefield injuries is a particular challenge. Moulage has the potential to assist in acquiring what could otherwise be very hard-to-come-by preparatory experience for distressing real-life emergencies medics and soldiers may encounter in the field. However, current approaches to moulage are limited in their ability to reflec ...

    STTR Phase II 2018 Department of DefenseDefense Health Agency
  5. Create Ultralong DNA Constructs in One Assembly Step

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 400

    Create Ultralong DNA Constructs in One Assembly Step Firebird Biomolecular Sciences LLCSteven ABenner Foundation for Applied Molecular EvolutionShuichi Hoshika AbstractFrost andampSullivan found aglobal market for DNA oligos at $million$million for genesPrivate investment in DNA synthesis companies like TwistGinkgoand DNA Script give collective valuations of several billion dollarsFederal public i ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Cytochlor/cytofluor: New Tumor Targeted Radiosensitizer

    SBC: HALOGENETICS            Topic: N/A

    DESCRIPTION (provided by applicant): Cytochlor Technology is about to enter a Phase I trial as a radiosensitizer of tumors of the oral cavity and oropharynx with NCI supervision. Our objective is to demonstrate Cytochlor's safety, selectivity and possible efficacy (although efficacy is not the goal of a Phase I trial). Our goal is to move Cytochlor Technology to a mutliinstitutional Phase II clini ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Evolutionary Analysis of Protein using HyperChem

    SBC: HYPERCUBE            Topic: N/A

    DESCRIPTION (provided by applicant): At the end of Phase II, we will launch a new commercial product: HYPERPROTEIN. HYPERPROTEIN will be built on an existing software platform, HYPERCHEM, now in its commercial Version 7.5. HYPERCHEM is used in both education and industry to apply molecular modeling and computational chemistry to molecules. The feasibility of placing the HYPERPROTEIN product on th ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Promoting Social Competence in Family Child Care Setting

    SBC: IRIS MEDIA INC            Topic: N/A

    DESCRIPTION (provided by applicant): The quality of experiences in child care has significant, lasting impact on children's social development. With the growing number of young children being served in family child care settings, it is imperative that the care provides a quality environment that nurtures children's social development. The purpose of this project is to develop a video-based train ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Nonpeptide Somatostatin Agonists for Retinopathy

    SBC: RFE PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic retinopathy (DR), the leading cause of adult blindness in the United States, is characterized by aberrant neovascularization ultimately leading to blindness. Similarly, choroidal neovascularization is seen in age-related macular degeneration (ARMD), which is the leading cause of blindness in the elderly. Currently, there is no drug treatment for either ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a T cell specific multiple sclerosis drug

    SBC: VIROGENOMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The broad, long-term objective of this project is to develop a new class of drugs for treatment of multiple sclerosis (MS). The lead compound in the current proposal is VG1000, a minimal recombinant TCR ligand (RTL) containing MHC class II (1(1 domains of HLA-DR2 covalently linked to myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide. This unique construc ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government